Regeneron Pharmaceuticals said the U.S. Food and Drug Administration has approved the use of Eylea for the treatment of diabetic macular edema.
European shares closed higher on Thursday, after a business activity index showed the euro zone rebounded in July.
Roche confirmed its full-year outlook, but posted profit that missed expectations following an impairment charge at its diagnostics business.
Severin Schwan, CEO of Roche, says the company would consider a large acquisition if the "price is right" despite concerns over high valuations.
Even as traders monitor the world's hot spots, corporate earnings news could be a positive for stocks in the week ahead.
Some of Monday's midday movers:
Allergan told its stockholders not to respond to Pershing Square Capital Management's proposal to replace a majority of the board.
Although treatments for Alzheimer's have struggled, drugmakers are still working in the space, with 67 medicines currently in development.
U.S. stocks closed mixed on Wednesday as the Dow and S&P 500 pushed into uncharted territory ahead of a government jobs report.
As the global population ages, some see investment opportunities in somewhat ghoulish bets the rates of cancer and other illnesses will rise.
CNBC's Meg Tirrell and Daniel O'Day, Roche Holdings COO, discuss the latest developments in immunotherapy and treating bladder cancer.
The announcement that GSK is planning to spend $350 million plus to get a slice of a U.K. biotech's cancer drugs has raised eyebrows.
Could things have turned out differently? Yes, according to one source in the AstraZeneca camp who pointed to a flaw in Pfizer's strategy.
Some stocks moved after the bell after abstracts for the American Society of Clinical Oncology meeting dropped Wednesday.
This week the headline appeared to have some tough news for RNA companies, but Alnylam remains undeterred about the potential of its treatments.
European shares closed lower on Tuesday, as Ukraine worries and fears about slowing demand in China weighed on stocks.
Swiss pharmaceuticals company Roche posted a rise in first-quarter sales but failed to meet market expectations as a strong Swiss franc hit results.
Severin Schwan, CEO of Roche, says he is "pleased" with the share price and results reported by the company.
The U.K. and U.S. governments spent millions stockpiling a flu drug that is no better than paracetamol, according to a new report.
An upbeat handover from Wall Street on Thursday inspired gains in most Asian shares on Friday.